Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome

Marketwired July 31, 2015

biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement

Marketwired July 21, 2015

biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement

Marketwired July 21, 2015

biOasis Engages Kilmer Lucas for Cross-Border Investor Relations

Marketwired June 8, 2015

biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"

Marketwired May 27, 2015

biOasis Provides Scientific Updates on Its Transcend Programs

Marketwired May 12, 2015

biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain

Marketwired April 21, 2015

biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score

Marketwired March 16, 2015

biOasis Announces Grant of Stock Options

Marketwired January 30, 2015

biOasis Announces the Release of an Analyst Report

Marketwired January 20, 2015

biOasis Engages Willow Tree Group to Assist with Global Business Development Activities

Marketwired October 7, 2014

biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation

Marketwired September 18, 2014

biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease

Marketwired September 9, 2014

biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis

Marketwired September 4, 2014

biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds

Marketwired August 29, 2014

WSA Talks to Two Dual-Listed Companies Making Waves

Marketwired August 21, 2014

biOasis Announces Non-Brokered Private Placement

Marketwired August 8, 2014

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain

Marketwired July 25, 2014

biOasis Appoints New Chief Financial Officer and Corporate Secretary

Marketwired June 20, 2014

biOasis Enters Investor Relations Agreement with Gale Capital Corporation

Marketwired June 16, 2014